[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Masuda
Norikazu
N
Department of Surgery, Breast Oncology Group, Osaka National Hospital.
D018943:Anthracyclines / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004164:Diphosphonates / Q000627:therapeutic use; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007258:Informed Consent; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D010166:Palliative Care; D010348:Patient Care Team; D011788:Quality of Life; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D017640:Silicates / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D014025:Titanium / Q000008:administration & dosage; D000068878:Trastuzumab
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D000069287:Capecitabine; D003841:Deoxycytidine; D004164:Diphosphonates; D000077143:Docetaxel; D005472:Fluorouracil; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D017640:Silicates; D043823:Taxoids; D014025:Titanium; D000068878:Trastuzumab; C103828:titanium silicide